Ridgeback Biotherapeutics
E468969
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
Statements (34)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
private company ⓘ |
| aimsTo |
address unmet medical needs in infectious diseases
ⓘ
rapidly develop countermeasures for outbreaks ⓘ |
| businessModel |
drug development
ⓘ
partnered commercialization ⓘ |
| collaboratedWith | Merck & Co. NERFINISHED ⓘ |
| countryOfOrigin |
United States of America
ⓘ
surface form:
United States
|
| developedProduct | molnupiravir NERFINISHED ⓘ |
| developsTreatmentFor |
COVID-19
NERFINISHED
ⓘ
Ebola virus disease NERFINISHED ⓘ serious infectious diseases ⓘ |
| focusesOn |
antiviral therapeutics
ⓘ
emerging viral diseases ⓘ immunotherapy ⓘ infectious diseases ⓘ |
| foundedBy |
Wayne Holman
NERFINISHED
ⓘ
Wendy Holman NERFINISHED ⓘ |
| hasKeyPerson | Wendy Holman NERFINISHED ⓘ |
| headquartersLocation | Miami, Florida, United States NERFINISHED ⓘ |
| indicationOfProduct | treatment of COVID-19 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| licensingActivity | licensed molnupiravir to Merck & Co. ⓘ |
| productType | oral antiviral drug ⓘ |
| researchArea |
RNA virus infections
ⓘ
biodefense-related pathogens ⓘ pandemic preparedness ⓘ |
| roleOfKeyPerson | Chief Executive Officer ⓘ |
| targetMarket |
global health
ⓘ
public health emergencies ⓘ |
| therapeuticModality |
immunotherapies
ⓘ
small-molecule antivirals ⓘ |
| worksOn | therapeutics for viral hemorrhagic fevers ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.